At CEO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CEO’ operating in the Health Diagnostics space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Co-Founder & CEO of Lively
Prior to Lively, Adam was the Chief Marketing Officer of 1stdibs – the world’s premier destination for unique, luxury design. At 1stdibs, Adam was instrumental in increasing the company’s revenue almost 10x; recruited and led a team of 100 and had full P&L responsibility for 1stdibs’ B2B business. Before 1stdibs Adam worked in senior roles at leading brands such as FreshDirect, Barnes & Noble and Century 21 real estate. At Century 21 he was responsible for developing and launching Century 21’s first website which at the time became the most recognized real estate website in the country and currently generates almost 50 million visits a year. After Century 21, Adam spent almost a decade at Barnes & Noble in increasingly senior roles ultimately becoming VP of Direct Marketing for both the retail stores and online. At Barnes & Noble, Adam managed some of the largest digital marketing programs in the industry, overseeing a budget of $100M. Adam graduated from the The Wharton School at the University of Pennsylvania with a degree in Economics.
Follow Adam Karp:
About Lively: Lively’s mission is to democratize, simplify and de-stigmatize the adoption and use of technically advanced hearing aids.
Co-Founder and CEO of Mammoth Biosciences
As co-founder and CEO of Mammoth Biosciences, Trevor Martin is focused on creating the world’s first CRISPR-based platform for disease detection, taking impactful CRISPR technology out of the lab and into the hands of doctors and consumers. Prior to co-founding Mammoth, Trevor completed his PhD in Biology at Stanford University, where he worked at the intersection of statistics and genetics. In addition to having taught a course in Statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic.
Follow Trevor Martin:
About Mammoth Biosciences: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Co-Founder and CEO of Ro
Zachariah is the CEO and cofounder of Ro. Founded in 2017, Ro is a healthcare technology company with a mission to provide personalized healthcare to everyone on the planet. Ro has three end-to-end verticals: Roman (men’s health), Rory (women’s health), and Zero (fighting addiction). As CEO and cofounder, Zachariah leads all medical and regulatory operations and oversees all verticals. Zachariah was named Inc. Magazine’s 30 Under 30, Business Insider’s 30 Under 40 in Healthcare, and a finalist in EY’s Entrepreneur of the Year. Ro was named #2 in Wellness in Fast Company’s World’s Most Innovative Companies 2019.
Follow Zachariah Reitano:
About Ro, Roman: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
President & CEO of Danaher
Thomas Joyce is President and Chief Executive Officer of Danaher Corporation, a position he assumed in September 2014. Thomas is responsible for the company’s strategic vision and leads the development and growth of Danaher’s global science and technology portfolio. Thomas has more than 20 years of Danaher leadership experience. Prior to his appointment as President and Chief Executive Officer, he served as Executive Vice President of Danaher Corporation, responsible for Danaher’s Water Quality platform and Life Sciences & Diagnostics segment. In this role, Thomas increased Danaher’s Water Quality revenue by over $1.5 billion and led the company’s major acquisitions of Beckman Coulter and AB SCIEX. Throughout his tenure, Thomas has also played a key role in developing and evolving the Danaher Business System, Danaher’s common operating philosophy. Thomas began his Danaher career in 1989 as a Project Manager in the Danaher Tool Group, and later transitioned into a manufacturing role. In 1995, Thomas became President of Delta Consolidated Industries. Following this assignment, he became President of Hach Company, the world leader in analytical instrumentation for drinking water and wastewater applications in 2001. In 2002, Thomas became a Group Executive and Corporate Officer with Danaher Corporation, which led to his transition to Executive Vice President in 2006. Prior to joining Danaher, Thomas worked as a management consultant at Anderson Consulting, where he worked with a large number of manufacturing businesses to implement lean tools and optimize transactional processes. Thomas was born and raised on the north shore of Chicago and earned his bachelor’s degree in Economics from the College of the Holy Cross in 1982. He and his wife, Claire, live in Washington, D.C. and have four children.
Follow Thomas Joyce:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Founder & CEO of PrettyLitter
Harvard University’s Center for Public Leadership Fellow. Founder and CEO of PrettyLitter.
Follow Daniel Rotman:
About PrettyLitter: PrettyLitter’s lightweight litter monitors feline health by changing colors when it detects potential issues through your cat’s urine.
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Sylvana Quader Sinha
Founder, Managing Director and CEO of Praava Health
Sylvana Quader Sinha is an attorney and entrepreneur with a passion for innovative, impactful approaches to governance and international development. Sylvana Quader Sinha has over a decade of experience leading diverse, interdisciplinary teams in international law, business, development, and government relations at major international law firms, management consulting firms, the World Bank, and think tanks in the Middle East and South Asia. She has independently advised private and sovereign clients on investments, projects, and disputes in frontier markets in the Middle East, Africa, and South Asia. She has advised governments in Afghanistan, the Middle East, and Asia on governance and legal reform, and counseled on investing to multinational and regional corporate clients; she has also moderated disputes in these and other markets on political, economic, and legal risk. Sylvana Quader Sinha also served as a foreign policy advisor to the 2008 Presidential campaign of then-Senator Barack Obama. Based out of New York City, Sylvana Quader Sinha’s legal practice included Investor-State and commercial arbitrations and international litigation, including as part of the International Arbitration Group at Weil, Gotshal & Manges LLP and the International Litigation and Arbitration Group at Lovells LLP (now Hogan Lovells LLP). Her clients consisted primarily of Fortune 500 companies and other multinational entities involved in disputes in the Middle East, Africa, and Asia. She has particular expertise in business and human rights. She represented a Canadian oil company in litigation involving allegations of international law violations in Sudan. She also conducted research on business and human rights issues for the Special Representative to the UN Secretary General. Additionally, Sylvana Quader Sinha served as a Term Member of the Council on Foreign Relations. She is a graduate of Columbia Law School, where she earned a certificate from the Parker School of Comparative and International Law. She also earned a master’s degree in Public Administration / International Development from Harvard’s Kennedy School and her Bachelor of Arts (with honors) in economics and philosophy from Wellesley College.
Follow Sylvana Quader Sinha:
About Praava Health: Praava Health is a patient-driven company disrupting the healthcare standard for Bangladesh’s 170 million citizens.
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Marc D. Grodman
CEO of Bio-Reference Laboratories
Follow Marc D. Grodman:
About Bio-Reference Laboratories: BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing .
CEO & Founder of Xealth
CEO at Xealth.
Follow Mike McSherry:
About Xealth: Xealth is a platform for digital health, enabling clinicians to prescribe and monitor digital tools from within the EHR workflow.
President, CEO of Bionano Genomics
Erik Holmlin has two decades of experience in the life science and health care industries. His expertise spans technology development and commercialization, global marketing, commercial operations, venture financing, mergers & acquisitions and intellectual property. Recently, he served as president and CEO of GenVault Corporation, a life science company bring innovative solutions to biosample management. He merged GenVault with IntegenX, Inc. in January of 2011. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was chief commercial officer at Exiqon A/S, where he was responsible for global sales, marketing, and clinical affairs for two businesses: Oncology Services in a CLIA lab and Consumables Business in Life Sciences Research. In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was director of chemistry, senior technology director, vice president of technology and business development, and vice president of marketing.
Follow Erik Holmlin:
About Bionano Genomics: BioNano Genomics develops nanoscale imaging and analytic platforms designed to analyze DNA and other genome-related peptides and proteins.
CEO, co-founder of Norbert Health
Alex is both a computer vision geek and a repeat tech entrepreneur. Born and raised in France, a proud Brooklynite today, Alex is currently CEO and co-founder of a stealth mode health tech startup. Alex is also helping several VC funds as a venture partner – Scrum Ventures, Serena. Prior to this project, Alex was leading the Artificial Intelligence team at Arlo. Alex was the CEO and founder of Placemeter, a New-York based startup that quantifies human activity in cities using computer vision and video feeds. Placemeter raised 8m of venture capital and was sold to Netgear in December 2016. Prior to placemeter, Alex co-founded LTU Technologies, a venture backed startup, pioneer in large scale image search by content. As a CTO then CEO of the company, Alex helped bring LTU to profitability in three years. LTU was successfully acquired by a Japanese company listed on the Tokyo Stock Exchange. Prior to LTU, Alex was a researcher in Computer Vision at INRIA. He also worked at Airbus, building vision based missile guidance systems. Alex holds an MSc and a PhD in Image Recognition from Telecom ParisTech, holds 9 patents in the field. Alex also advises various startups in New York, and is a mentor of the Techstars NYC program. Prior to LTU, Alexandre was a researcher at INRIA in Paris, and a missile guidance engineer at Aerospatiale, now EADS. Alexandre holds a PhD in Computer Vision from Telecom Paristech and 10 patents in the field.
Follow Alexandre Winter:
About Norbert Health, Serena, Stealth mode health tech startup: Norbert Health develops a home medical pod that monitors the health of families using contactless sensors.
Roy Paxton Yih
Co-Founder and CEO of Biocare Medical
Roy Paxton Yih, BS, MA, co-founded Biocare Medical, LLC in 1997 and serves as its Chief Executive Officer and President. Roy Yih served as a Director of Sales & Marketing at Biocare Medical LLC. Roy Yih is primarily involved at sales, marketing and business development activities. He holds a BS Degree in Biochemistry from U.C. Davis and an MBA from the University of Santa Clara.
Follow Roy Paxton Yih:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
CEO, Co-Founder of Viz
Dr Mansi is a former Neurosurgeon and the CEO of Viz.ai an Applied AI Healthcare company.They recently received FDA clearance for the first ever AI aided triage and notification platform, opening the door to AI in acute emergency healthcare. Chris is a clinician innovator, entrepreneur and optimist focused on increasing healthcare access, building and supporting great teams and improving provider experience. Viz.ai builds clinician facing products that enable and empower doctors, allowing them to provide the best care to patients, everytime, everywhere.
Follow Chris Mansi:
About Viz: Viz is a medical imaging company that helps optimize emergency treatment using deep learning technology.
Co-Founder & CEO of Sesame
David Goldhill is the founder and CEO of Sesame.
Follow David Goldhill:
About Game Show Network, Sesame: Sesame is a healthcare superstore, with over 10,000 medical practices offering affordable prices for care in-person or online.
Chief Executive Officer of Freenome
Mike brings nearly three decades of experience to his role as Freenome’s Chief Executive Officer, building on a proven record of delivering transformative diagnostic technologies that help clinicians drive better outcomes for their patients. Previously, Mike served as the company’s Chief Business Officer, where he led Freenome’s corporate and business development, product management, clinical development and operations, program management, and marketing teams. He also oversaw partnerships with biopharma companies, academic medical centers, and health systems where our multiomics platform is deployed to move research and medicine forward.
Follow Mike Nolan:
About Freenome, Freenome, Freenome: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Founder / CEO of Kit.com
Founder/CEO @Kit.com, Engineer #15 @Facebook
Follow Philip Fung:
About Kit.com: Kit.com is a home medical exams, delivered. Kit makes health testing simpler, easier and more reliable for your patients.
Co-Founder and CEO of Mojo Vision
Follow Drew Perkins:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Co-Founder & CEO of Notable
Pranay Kapadia is a VP of Product at Blend Labs.
Follow Pranay Kapadia:
About Notable: Notable is an AI-powered health start-up that automates and digitizes every physician-patient interaction.
Founder and CEO of Respira Labs
Follow Maria Artunduaga:
About Respira Labs: Respira Labs is building an AI-powered sensor platform to track, predict, and prevent chronic lung disease.
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
CEO & Founder of Virus Geeks Inc.
Follow Frank Lee:
About CarSnatch, Virus Geeks Inc.: SaaS, Mobile App, BioHealth, Information Technology
Founder and CEO of Genapsys
Hesaam is the Founder and CEO of GenapSys Inc. He is an inventor of electronic DNA sequencing, a technology he developed during his PhD work at Stanford. Hesaam has dedicated the past decade of his life to the development of this novel DNA sequencing technology, which has at its core the convergence of multiple fields of science – engineering, chemistry, biology, and computing. Hesaam incubated the technology at the Stanford Genome Technology Center for a period of six years before securing licenses to the IP and incorporating GenapSys in January of 2010. He has grown GenapSys from just a handful of employees working out of Menlo Labs incubator space, to over 50 employees across seven functional teams. In 2012, Hesaam partnered GenapSys with StartX, an accelerator for the development of Stanford’s top entrepreneurs. He has raised approximately $50M for GenapSys in Seed, Series A, and Series B rounds of financing. Hesaam holds a PhD and MS in Electrical Engineering, and MSc Management degree, all from Stanford University. He earned his BS in Electrical Engineering with Honors from Sharif University of Technology in Tehran, Iran. When he is not at GenapSys HQ (which is rare!) you can find Hesaam spending time outdoors, hiking or spending time with family and friends. He is also a great lover of poetry, his favorite of which are poems by the Persian poet Saa’di.
Follow Hesaam Esfandyarpour:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
CEO and Co-Founder of Hura Imaging
Marc Korczykowski is Hura Imaging’s Co-Founder and CEO.
Follow Marc Korczykowski:
About Hura Imaging: Hura Imaging develops and commercializes novel CT technology that decreases radiation dose significantly in patient management.
Co-Founder, President, & CEO of ChromaCode
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Follow Greg Gosch:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Co-Founder and CEO of Clear Labs
Sasan combined his academic expertise and passion for healthy living when he co-founded Clear Labs with a mission to set a new paradigm for food safety and quality. Prior to serving as the CEO of Clear Labs, he worked in the Advanced Research department at Illumina. Sasan earned his PhD in Genomics from Princeton and holds multiple patents and publications in the field.
Follow Sasan Amini:
About Clear Labs: Clear Labs is a provider of a fully-automated sequencing platform for turnkey diagnostics.
Founder & CEO of Arterys
Fabien Beckers is the CEO and co-founder of Arterys, a cloud/deep learning startup that is disrupting the medical imaging space and building image-based precision medicine tools. Fabien has led the growth of the company from four co-founders to a team of 34 today. Under his leadership, the company has become a pioneer in cloud-based medical imaging software, offering the first FDA-cleared end-to-end cloud infrastructure for medical imaging. They key advantages of the platform being automatic aggregation of real-world data and ability to scale and distribute the processing of increasingly large, complex datasets. Fabien’s vision for the company is to accelerate data-driven medicine by building precision medicine tools based on the consistent quantification of medical image features in combination with molecular, genomics and patient history data. Fabien holds a PhD in Quantum Physics from the University of Cambridge and a masters of business from Stanford University.
Follow Fabien Beckers:
About Arterys: Arterys is a medical imaging platform to deliver clinical AI products over the internet.
Co-Founder & CEO of Diagnose Early
Follow Chris Wheeler:
About Diagnose Early, WISC Partners: Diagnose Early provides detection technologies for cancer, neurological, and infectious diseases.
Co-Founder, President & CEO of Promaxo
Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Cricking, MedDx and HealthyX and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.
Follow Amit Vohra:
About 8chili, Neuro42, Promaxo, TriOcula Technologies: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
CEO of MedTech Innovator
Follow Paul Grand:
About MedTech Innovator: MedTech Innovator is the largest lifescience accelerator in the world for medical device, digital health, and diagnostic companies
Co-Founder & CEO of Inflammatix
Tim Sweeney, MD, PhD is the co-Founder & CEO of Inflammatix, Inc., which focuses on using robust informatics and machine learning to derive novel HostDx™ diagnostics based on ‘reading’ patterns in the immune system. Inflammatix’s first tests are focused on diagnosing acute bacterial and viral infections and sepsis. The company is funded by Khosla Ventures, Stanford-StartX Fund and the U.S. government’s DARPA program. Tim Sweeney completed his MD and PhD at Duke University, after which he was a surgery resident at Stanford. While training as a surgeon, he became frustrated with the limitations of current diagnostic tools for infection. During his residency, he completed a postdoctorate MS in Biomedical Informatics, mentored by Dr. Purvesh Khatri. Together they designed the custom informatics algorithms for sifting through heterogeneous ‘big data,’ which formed the core technology on which Inflammatix is based.
Follow Tim Sweeney:
About Inflammatix: Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by reading the immune system.
Co-founder & CEO of PathAI
Andrew Beck earned a Bachelors of Arts in History from Brown University in 2002 and completed a Masters of Medical Science in Biostatistics and a Medical Degree from Brown Medical School in 2006. He completed his residency in Anatomic Pathology and clinical fellowship in Molecular Genetic Pathology from Stanford in 2010.He then joined the Advanced Residency Training at Stanford program and completed a PhD in Biomedical Informatics from Stanford University in 2013, working with Professor Daphne Koller. In 2011, he was appointed as an Assistant Professor in the Departmet of Pathology at Harvard Medical School and the Beth Israel Deaconess Medical Center. In 2016, he was promoted to Associate Professor. In 2016, Dr Beck co-founded PathAI, a company that develops artificial intelligence technology for pathology, where he serves as President and CEO.
Follow Andrew Beck:
About Beth Israel Deaconess Medical Center, PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Founder & CEO of Parsley Health
Robin Berzin, MD is the founder and CEO of Parsley Health, a primary care medicine provider with a data-driven, whole body approach. A summa cum laude graduate of the University of Pennsylvania, she completed medical school at Columbia University’s College of Physicians and Surgeons and trained in internal medicine at Mount Sinai Hospital in New York City. Dr. Berzin also trained with the Institute for Functional Medicine, where she acts as an advisor on digital technology. She speaks regularly for organizations including Stanford Medicine X, Health 2.0, Rock Health, Summit Series, and Further Future about how health care can be reinvented.
Follow Robin Berzin:
About Parsley Health: Parsley Health is redesigning primary care by integrating the latest in medical testing, technology and nutrition research.
Chief Executive Officer of Biohaven Pharmaceutical
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.
Follow Vlad Coric:
About Biohaven Pharmaceutical: Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
CEO/Chief Nerd of BioFire Diagnostics
Kirk Ririe founded BioFire Diagnostics, Inc. (BFDX) in 1990 and has made key inventive contributions to its products. At BioFire, he has established an open and risk-tolerant business culture to promote and reward innovation. Mr. Ririe is the recipient of the National Tibbetts Award for the Company’s outstanding contribution to the Small Business Innovation Research program (1999), the Franklin Jefferson Award in Science and Technology Innovation (1999), and the Western-region Ernst & Young Entrepreneur of the Year Award (2004). Mr. Ririe holds a B.S. in Chemistry from the University of Utah.
Follow Kirk Ririe:
About BioFire Diagnostics: BioFire Diagnostics is a biotech company that detects pathogens and mutations for molecular diagnostics.
CEO of Dana-Farber Cancer Institute
Edward Benz, Jr. M.D. is President and Chief Executive Officer of Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners Cancer Care as well as Principal Investigator and Director of Dana-Farber/Harvard Cancer Care and a member of the Governing Board of Dana-Farber/Children’s Hospital Cancer Center. An internationally recognized hematologist, Benz received his training at Brigham and Women’s Hospital, the National Institutes of Health, and Harvard Medical School. He is board certified in Internal Medicine and Hematology. Benz continues to be an active NIH funded investigator. He has authored over 300 peer reviewed articles, reviews, chapters and abstracts. He is a co-editor of Hematology: Principles and Practice and of the Oxford Textbook of Medicine for which he and his colleagues received the Royal Society of Authors Textbook Award. He is an associate editor of the New England Journal of Medicine. Benz’ accomplishments have been recognized by a number of distinctions, including membership in the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Science. He is a past president of the American Society of Hematology, the American Society of Clinical Investigation and the Association of American Cancer Institutes.
Follow Edward Benz:
About Dana-Farber Cancer Institute, Harvard Medical School: Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
Chairman & CEO of Johnson & Johnson
Follow Alex Gorsky:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Co-Founder & CEO of SolveBio
Mark Kaganovich is the Co-Founder & CEO at SolveBio.
Follow Mark Kaganovich:
About SolveBio: SolveBio deploys technology and on-demand expertise to drive precision medicine. We monitor, gather, and secure Genomic Intelligence.
CEO, Co-Founder of VoyagerMed
Anthony has over 15 years of experience as a Private Wealth advisor on Wall Street. He left Forbes Family Trust in 2014 to start VoyagerMed and has been spearheading the company’s digital operations ever since. Contact Anthony at [email protected]
Follow Anthony Girand:
About VoyagerMed: A medical tourism marketplace faciliating access to life changing medical innovations from trusted doctors around the world.
CEO of Accolade
Rajeev Singh is Chief Executive Officer at Accolade, the leading technology-enabled consumer healthcare engagement services company for large employers, payers and provider organizations. He was most recently co-founder, president and chief operating officer of Seattle-based Software-as-a-Service (SaaS) travel and expense management firm Concur, the eighth-largest SaaS company in the world. Rajeev co-founded Concur, the global leader in travel and expense management, in 1993. His early years in the company were focused in the product management and development organizations. In the 20 years that followed, he worked in nearly every role in the business – culminating in his final role as president, chief operating officer and board director for the last nine years of his tenure. During that timeframe, the company grew from $60mm in revenues to over $800mm in revenues before being acquired by SAP AG for $8.3bn in 2014. He graduated from Western Michigan University with a BSE. Today, he serves on the boards of Apptio, a SaaS technology business management solutions provider, and on The Seattle Children’s Hospital Foundation.
Follow Rajeev Singh:
About Accolade: Accolade features personalized health and benefits solutions that help to improve experience, outcomes, and healthcare cost for employers.
CEO of Bluebird Bio
Follow Nick Leschly:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
President & CEO of ClearChoice Holdings
Kevin Mosher is an executive with more than 20 years experience in the dental and medical technology industries, and currently serves as President and CEO of ClearChoice Holdings, a nationwide network of dental implant centers that specialize in the treatment of the fully edentulous. Following a five-year stint as a logistics officer in the US Navy, Kevin began his medical career in sales and marketing with Baxter Healthcare, Johnson and Johnson (Ethicon and Advanced Sterilization Products), and Masimo Corporation. As President of startup medical device manufacturer Masimo Corp, Kevin led the commercial activities of an organization that grew from $12 – $70M during his three-year tenure. Following Masimo, he served as President of dental implant manufacturer Nobel Biocare’s North American division where divisional revenues more than doubled from $140M to $315M over a six-year period. Prior to his current position at ClearChoice, Kevin served as President and CEO of medical device startup DFINE, Inc, a company focused on the minimally invasive treatment of diseases of the spine. He holds a B.S. in Applied Engineering Sciences from the U.S. Naval Academy.
Follow Kevin Mosher:
About ClearChoice Holdings: ClearChoice is a network of dental treatment centers that provide innovative and quality dental implant care across the United States.
President & Chief Executive Officer of Abbott
Follow Robert Ford:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
CEO of Prevail Therapeutics
Franz Hefti is the CEO of Prevail Therapeutics and he holds a Ph.D. from the University of Zurich and completed his postdoctoral research at the Massachusetts Institute of Technology.
Follow Franz Hefti:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Chief Executive Officer of ImmunityBio
In January 2021, Richard (Rich) Adcock was named Chief Executive Officer of ImmunityBio. He was the former CEO of NantKwest and has been in healthcare leadership positions for for 30 years. He is known for his experience in developing cultures centered on quick, strategic innovation. He is a Six Sigma Master Black Belt, ensuring that such initiatives are complemented by strong quality systems across the organization. Adcock formerly served as CEO of Verity Health, where he oversaw a successful reorganization process. He started his career in 1992 as a co-founder and Vice President of Research and Development for Micro Medical Systems, where he helped pioneer the development of early Cardiology Electronic Medical Records. Following the company’s purchase by GE Healthcare in 1999, Adcock acquired prominent responsibilities in healthcare innovation. He eventually received an MBA in Healthcare Management and joined Sanford Health, where he was President and later Chief Innovation Officer.
Follow Richard Adcock:
About ImmunityBio, NantKwest: ImmunityBio is an offshoot of Soon-Shiong’s NantWorks conglomerate, developing molecular-level cell-based treatments for diseases.
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Co-Founder & CEO of Zerigo Health
Advisor at Cooler Heads Care & Chief Business Officer at Mindera.
Follow Martyn Gross:
About Dthera Sciences, MiNDERA Corporation, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Founder & CEO of Getlabs
Kyle Michelson is the Founder and CEO of Getlabs. He previously founded Streamup, a live video streaming platform backed by Y Combinator, and studied at the University of Southern California and London School of Economics.
Follow Kyle Michelson:
About Getlabs: Getlabs is the nationwide leader for at-home diagnostic collections. Patients can book a nearby phlebotomist to draw their labs for Labcorp and Quest. Healthcare organizations and providers can dispatch medical specialists to their patients and collect labs, vitals, biometrics, and more.
Co-Founder & CEO of Eko Health
Connor Landgraf is the co-founder and CEO of Eko.
Follow Connor Landgraf:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Co-Founder and CEO of Pendulum Therapeutics
Colleen Cutcliffe is the Co-Founder and CEO of Pendulum Therapeutics.
Follow Colleen Cutcliffe:
About American Diabetes Association, California Life Sciences Association, Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Chief Executive Officer of Farcast
Maneesh most recently served as Chief Operating Officer and Director at Exact Sciences until 2018. Exact Sciences’ focus is the early detection and prevention of cancer. Exact’s lead product, Cologuard®, was developed in collaboration with the Mayo Clinic and is now widely available in the US as a frontline screening method for colorectal cancer, reimbursed by both Medicare and all major insurers. Previously, Maneesh worked for Third Wave Technologies, Inc., a molecular diagnostics company, from 2003 until its acquisition by Hologic, Inc. in July 2008. Third Wave Technologies developed an HPV product for cervical cancer screening. During his time at Third Wave, Maneesh was responsible for business strategy and commercial operations before being promoted to chief financial officer in January 2006. Maneesh earned a BA in economics from the University of Chicago and an MBA from the Kellogg School of Management at Northwestern University.
Follow Maneesh Arora:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
Founder & CEO of Cue
Ayub Khattak is the CEO and founder at Cue.
Follow Ayub Khattak:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
CEO and Co-Founder of Mirvie
Maneesh Jain currently works as Chief Executive Officer and the Founder of Mirvie. He previously worked at Cirina (Grail) as CEO and President.
Follow Maneesh Jain:
About Mirvie: Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
Sarah Jones Simmer
CEO of Found
CEO @ Found. Sarah has spoken at SXSW, the Global Partnership for Education, and UN special sessions on topics ranging from girls’ and women’s rights to the future of ethical business. She has a Masters’ in Public Policy from Northwestern University. She used to run marathons and has completed an Ironman, but now spends her time outside of work raising two amazing young daughters.
Follow Sarah Jones Simmer:
About Found: Found is dedicated to improving people’s overall wellbeing by making evidence-based weight loss accessible and affordable.
Founder & CEO of DX Medical Solutions
Follow Giuliano Senese:
About DX Medical Solutions: Medical Technology Startup
CEO of RapidAI
Don Listwin is the CEO of RapidAI. Don Listwin is also a distinguished networking industry veteran with more than 20 years of experience, including a decade at Cisco Systems, and served as president and CEO of Openwave Systems Inc., the world’s leading provider of open software and services for the communications industry. Listwin helped launch NetAid, an innovative nonprofit organization that partners with the United Nations to provide corporations, groups and individuals concrete ways to fight extreme poverty in developing countries. Listwin is the founder of the Canary Foundation and a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center in Seattle Washington.
Follow Don Listwin:
About Canary Foundation, RapidAI: RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients.
Co-Founder & Co-CEO of Imagen Technologies
Alex is a Co-Founder and the Co-CEO of Imagen. Prior to co-founding Imagen, Alex worked as the Head of the Hospital for Special Surgery’s Value Analytics and Management Office. Alex began his career at Bridgewater Associates where he was a member of the Core Management Team. Alex received his bachelor’s degree from the London School of Economics.
Follow Alex Dresner:
About Imagen Technologies: Powering the future of primary care
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Chairman, President and CEO of PrimeGen Biotech
Tom Yuen is a proven serial entrepreneur who has founded several successful publicly traded companies including AST Research Inc. and SRS Labs, Inc. (NASDAQ: SRSL). Tom Yuen received his Bachelor of Science degree in Electrical Engineering from the University of California, Irvine in 1974. Tom Yuen Has received many honors including: Director of the Year, Orange County Forum for Corporate Directors (1997), Top 25 Executives, Consumer Industry, Computer Reseller News Magazine (1991 & 1987), The UCI Medal (1990), The UCI Outstanding Engineering Alumni Award (1987), and The UCI Distinguished Alumnus Award (1986).
Follow Thomas Yuen:
About PrimeGen Biotech: PrimeGen Biotech is a privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells.
President & CEO of PrimeGen Biotech
Yuen is a proven serial entrepreneur who has founded several successful publicly traded companies including AST Research Inc. and SRS Labs, Inc. (NASDAQ: SRSL). Yuen received his Bachelor of Science degree in Electrical Engineering from the University of California, Irvine in 1974. Yuen Has received many honors including: Director of the Year, Orange County Forum for Corporate Directors (1997), Top 25 Executives, Consumer Industry, Computer Reseller News Magazine (1991 & 1987), The UCI Medal (1990), The UCI Outstanding Engineering Alumni Award (1987), and The UCI Distinguished Alumnus Award (1986).
Follow Tom Yuen:
About PrimeGen Biotech: PrimeGen Biotech is a privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells.
CEO & Founder of Sema4
Eric Schadt is Chief Scientific Officer of Pacific Biosciences and Director of the Institute for Genomics and Multiscale Biology and Chair of the Department of Genetics and Genomics Sciences at The Mount Sinai Medical Center. He oversees the scientific strategy for Pacific Biosciences, including creating the vision for next-generation applications of the company’s technology, contributing to the evolution of Pacific Biosciences’ transformative sequencing technology, and playing a key role in the company’s strategic relationships. At Mount Sinai, Eric is creating a world-class data analytic center where researchers can query and learn from data using cutting-edge technologies like next generation sequencing to create disease models and ultimately help develop and improve the diagnosis and treatment of patients. He is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Eric Schadt joined Pacific Biosciences in May 2009 from Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, where he was Executive Scientific Director of Genetics. Eric Schadt’s work at Rosetta involved the generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations to construct the molecular networks that define disease states and link molecular biology to physiology in ways that can impact clinical medicine. Eric Schadt has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. Prior to joining Rosetta, Eric Schadt was a senior research scientist at Roche Bioscience. He received his BA in applied mathematics and computer science from California Polytechnic State University, his MA in pure mathematics from UCLA, and his Ph.D. in bio-mathematics from UCLA.
Follow Eric Schadt:
About Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Sage Bionetworks, Sema4: Sema4 uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
President & CEO of C4 Therapeutics
Follow Jason Fisherman:
About AlloMek Therapeutics, C4 Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Raymond W. Cohen
CEO of Axonics Modulation Technologies
Mr. Raymond Cohen is presently Chief Executive Officer of Vessix Medical, Inc.. He has over 28 years of experience in the medical technology field focused on new product development, creation of intellectual property, venture financing, sales and marketing, strategic planning and mergers and acquisitions. For the decade prior to 2006, Cohen served as Chairman and CEO of Nasdaq-listed Cardiac Science, Inc., which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche’s Fast 500 listing and was recognized by Inc. Magazine on “The Innovation 50 – a listing of the most inventive small companies in entrepreneurial America”. Cohen also serves as member of the board of directors of Cardiogenesis Corp, BioLife Solutions, Inc. and Syncroness, Inc. Mr. Cohen holds a B.S. in Business Management from the State University of New York at Binghamton and is an Accredited Public Company Director.
Follow Raymond W. Cohen:
About Axonics Modulation Technologies, BioLife Solutions: Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
Cofounder & CEO of Vetcove
Cofounder and CEO of Vetcove.
Follow Alexander Kates:
About Vetcove: Vetcove is the largest B2B veterinary marketplace, enabling veterinary hospitals to compare and buy supplies from all of their vendors.
Co-Founder & CEO of Qure AI
Prashant Warier is a Co-Founder and the Chief Executive Officer at Qure.ai.
Follow Prashant Warier:
About Fractal Analytics, Qure AI: build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients
Founder , President & CEO of DiabetOmics
Dr. Nagalla is the principal founder and chief executive officer of DiabetOmics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums of biotechnology, genomics, and proteomics. Dr. Nagalla has 20+ years of broad multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his M.D. from the All-India Institute of Medical Sciences, New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.
Follow Srinivasa Nagalla:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Co-Founder, Chief Executive Officer, Chairman, and Director of LumiraDx
Ron Zwanziger, a strategic visionary and entrepreneur, is the CEO of LumiraDx, which he co-founded in 2014. He previously founded and led numerous successful diagnostic firms, including Alere, Inverness Medical Technology (which was acquired by Johnson & Johnson in 2001), and MediSense, the first company to introduce an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.
Follow Ron Zwanziger:
About LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Dr Toby Hamilton
Founding Partner & Chief Executive Officer of Emerus Hospital Partners
Dr. Hamilton is a founding partner, member of the board of directors and Chief Executive Officer of Emerus Holdings Inc. A Fellow of the American College of Emergency Physicians and Board-Certified in emergency medicine, Dr. Hamilton has previously served as a Regional Medical Director of Cypress Creek Emergency Care Center and was a practicing physician at Denton Regional Medical Center in Denton, Texas. Dr. Hamilton graduated Magna Cum Laude with an undergraduate degree in Biology at Texas Tech University in Lubbock, Texas. He earned his medical degree from Texas Tech University Health Science Center School of Medicine in El Paso and Lubbock and completed his residency at Texas Tech University Health Science Center School of Medicine in El Paso.
Follow Dr Toby Hamilton:
About Emerus Hospital Partners: Emerus Hospital is an emergency care facility providing prompt diagnosis, treatments and advanced emergency care services for patients.
CEO of Omniox
Jonathan Winger is co-inventor of the H-NOX technology, company Co-Founder, and Senior Director of Biochemistry and Manufacturing. He directs the design and biochemical characterization of protein variants with the kinetic and stability properties appropriate for each of the diseases in which H-NOX will be used, as well as oversees in-house protein production and quality control. He also manages the transfer of upstream and downstream processes for scale-up and GMP manufacturing of material for toxicology studies and clinical trials. Jonathan has 18 years of experience in diverse biochemical and biophysical methods for production and study of H-NOX and other heme proteins. He has published a number of peer reviewed research papers, co-authored several book chapters, and is an inventor on multiple patents. Prior to Omniox, he was an American Heart Association Postdoctoral Fellow with John Kuriyan at the University of California, Berkeley, where he developed expertise in biophysical techniques including X-ray crystallography, small-angle X-ray scattering, and NMR. He obtained his PhD in Medicinal Chemistry with Michael Marletta at the University of Michigan, where he used spectroscopy and enzymology to investigate the role of soluble guanylate cyclase (sGC), an H-NOX domain-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox.
Follow Jonathan Winger:
About Omniox, Omniox: Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma.
Founder & CEO of 10.10.10
Tom Higley, a Denver-based entrepreneur, has founded six tech startups over the course of the past 20 years, including Service Metrics (acquired by Exodus Communications for $280 million) and StillSecure (aka Latis Networks). He has been a waiter, a janitor, a carpenter, a painter, a GM auto worker, a music store manager, a teacher, a guitar player, a lawyer, a CEO, a board member, and a mentor. He has been a mentor in the Boulder TechStars program since 2006 and at Galvanize since its opening in 2012. Tom earned his bachelor’s degree at the University of Michigan, 1985, and his juris doctor at Harvard Law School, 1989. He continues to start companies and advise founders of startups.
Follow Tom Higley:
About 10.10.10, Iggli, X Genesis: 10.10.10 gives impact entrepreneurs the context and tools to develop market-based solutions.
Co-Founder and CEO of Blueberry Pediatrics
Harrison Gordon graduated from Northwestern University and worked for Microsoft as a program manager and Google as a product manager. With a family full of doctors and both parents practicing physicians based in Florida, Harrison wanted to use his background and expertise to create a company that uses online services to create a better life for everyone. In his spare time, Harrison enjoys cooking, hiking, and playing with his 1-year-old rescue dog Riley.
Follow Harrison Gordon:
About Blueberry Pediatrics: Blueberry Pediatrics provides parents with live access to top pediatricians for a flat monthly rate.
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
CEO & Co-Founder of Nines
David was CEO of Udacity from founding in June 2011 through May 2012 and President until April 2013. As CEO, he built the team to 30 employees, enrolled the first 250,000 students in 195+ countries, and launched the first 12 classes, the first jobs program for MOOC graduates, and the first certified exams for MOOCs in partnership with Pearson VUE. At Stanford, he co-founded the robotic car team that won the 2005 DARPA Grand Challenge — which later became the Google Car — and received a Ph.D. in Computer Science from Sebastian Thrun. He also raised the first $100K in funding and recruited the founding team for WiFi SLAM, which was acquired by Apple.
Follow David Stavens:
About Nines: Nines is the first-of-its-kind radiology practice. Radiologists + Data Scientists + Engineers. Trusted partner.
Founder and CEO of iFirst Medical Technologies
Founder and CEO, iFirst Medical Technologies.
Follow Luke Joseph:
About iFirst Medical Technologies: iFirst Medical Technologies is a lifesaving blood analysis platform providing a new standard-of-care in coagulation diagnostics.
Co-founder and Chief Executive Officer of Ceribell
Follow Xingjuan Chao:
About Ceribell: Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.
Founder and CEO of Curai Health
Neil Hunt has been at Netflix since 1999 and serves as Chief Product Officer, leading the product team, which designs, builds and optimizes the Netflix experience. Prior to Netflix, Neil worked from 1991 in various engineering and product roles at the software test tool companies Pure Software and its successors, Pure Atria and Rational Software. Before that, Neil was engaged in research in computer vision and image processing at the University of Aberdeen, Schlumberger Palo Alto Research Labs and Teleos Research. Neil has been a non-executive member of Logitech’s board of directors since September 2010. He holds a Doctorate in Computer Science from the University of Aberdeen, U.K. and a Bachelor’s degree from the University of Durham, U.K.
Follow Neil Hunt:
About Curai Health: Curai Health is a virtual care company that uses artificial intelligence to provide chat-based primary care at a lower cost.
Co-Founder, President & Chief Executive Officer of HiberCell
Alan Rigby is a passionate and innovative oncology leader with over 20 years of academic and industry experience in the area of data driven oncology drug discovery from concept to clinical candidate to genetically enabled first-in-man studies. Dr. Rigby is committed to leveraging patient material and data for use in the identification, stratification and development of ‘next generation’ cancer therapeutics for use in responder populations. This ‘commitment’ has resulted in clinically validated large and small molecule therapeutics for several cancer indications. Most recently, Alan led a prioritized and focused effort to translate ‘Natures Intracellular Biologic’ into transformative medicines for oncology and antibiotic resistance while chief scientific officer of Warp Drive Bio., a Cambridge based biotechnology company that was recently acquired. Alan joined Warp Drive Bio following a tenure as senior vice president and chief scientific officer at Synta Pharmaceuticals. While at Synta Alan led research and development efforts for Synta’s HSP90 clinical candidate, Ganetespib, as well as restructuring the preclinical small molecule drug conjugate platform. Prior to joining Synta, Dr. Rigby was vice president, global antibody drug conjugate biology, and head of external innovation for oncology research at the New York site for Eli Lilly and Company. Before launching his biotech/ pharmaceutical career Dr. Rigby was a National Institutes of Health (NIH) funded assistant professor and principal investigator at Beth Israel Deaconess Medical Center, Harvard Medical School. While at Harvard Medical School, he founded and directed the Drug Discovery and Target Validation Program within the Beth Israel Deaconess Medical Center. As a mentor and advisor Alan continues to work with numerous organizations to assemble and chair scientific conferences with a focus on translating innovative science and oncology-centric platforms into robust and durable clinically validated strategies. Alan Rigby is on the Editorial Advisory Board for Future Medicinal Chemistry, was North American Editor for Current Computer Aided Drug Discovery and has published more than 55 scientific papers, a book chapter and has 12 patents that have published or are pending. Alan holds an Honors BSc. in Biochemistry from the University of Western Ontario in London, Ontario, Canada and a Ph.D. in Biochemistry from the same University.
Follow Alan Rigby:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Chief Executive Officer of Grail
Follow Robert Ragusa:
About Grail, Illumina: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Co-Founder and CEO of Story Health
Thomas Stanis is the CEO and Co-Founder of Story Health. Prior to joining Verily, he spent nine years working on core Google products and five years at Electronic Arts. Throughout his career, Tom’s focus has been on improving the user experience, performance, and scalability of systems through cross-functional collaboration. He received his B.S. from UW Madison.
Follow Thomas Stanis:
About Story Health: Story Health helps specialists to understand medical situations and make clinical decisions that are through virtual protocols.
President and CEO of CorVista Health
Don Crawford, President & Chief Executive Officer, is a seasoned medical device executive with a proven track record of excellent results driven leadership through team efforts and focused execution. Don previously founded and led Sapheon Inc., a cardiovascular-focused medical device company, from inception to $238 million acquisition by Covidien in 2014. His career started with Medtronic and included sales and marketing positions of increasing responsibility with Guidant Corporation, Ventritex, and Intermedics, including an international sales director role in charge of a $100 million cardiovascular business. Don received his B.Ch.E. in Chemical Engineering from Georgia Tech and M.B.A. from Emory University.
Follow Don Crawford:
About CorVista Health: CorVista Health uses artificial intelligence to develop a completely new form of medical imaging for coronary artery disease.
CEO of Workpath
Eddie Peloke is the CEO at Workpath.
Follow Eddie Peloke:
About Workpath: Workpath is a computer software company that specializes in healthcare technology and workforce management.
Chief Executive Officer of Seno Medical Instruments
Thomas Umbel is Chief Executive Officer of Seno Medical Instruments, Inc. Tom Umbel brings more than 30 years of medical device and diagnostics leadership experience to Seno Medical. He has lead several start-up companies, including one through a successful acquisition. He has also managed large organizations through significant growth leading both the strategic development and M&A efforts in his previous roles. Tom was most recently the VP of Business Development for Bioventus, a privately held ortho-biologics company in Durham, NC. Tom has led the Business Development efforts at both Bioventus and Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped to grow Hologic from a small single-product company with $100 million in revenue to a large diversified company with more than $2.5 billion in sales in his 15 years with the company. Prior to Hologic, Tom was the President of Direct Radiography Corp. (DRC). He led the development and commercialization of the digital x-ray detector technology, which he ultimately sold to Hologic in 1999. This company’s technology became the core to Hologic’s market leading digital mammography system and was the engine to Hologic’s significant growth. Prior to DRC, Tom worked at Sterling Diagnostic Imaging for 3 years and DuPont for 20 years. At those two companies, Tom held senior management positions in operations, engineering, sales and marketing. Tom has a BS in Chemical Engineering from Grove City College.
Follow Thomas Umbel:
About Seno Medical Instruments: Seno Medical is commercialization efforts in opto-acoustic imaging of breast cancer.
CEO and Co-Founder of STRIVE
Nikola Mrvaljevic is the CEO and Co-Founder of Strive Tech.
Follow Nikola Mrvaljevic:
About STRIVE: STRIVE is the only data platform proven to optimize muscle performance for elite athletes and teams.
CEO of Xip
Follow Octavian Florescu:
About Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Founder , CEO & President of Akonni Biosystems
Dr. Daitch is the Founder of Akonni and has served as the CEO and Board member since its inception in 2003. He has 26 years of product development experience in integrated biosensors encompassing a broad range of disciplines including chemistry, biology, biomaterials, engineering, and chemical/biological defense. He manages and leads multidisciplinary teams of scientists and engineers focused on the development of next-generation in-vitro diagnostic devices. Dr. Daitch has experience in developing a wide variety of sensor system products for remote autonomous or point-of-use detection of complex samples employing miniaturized analyte purification, and specialty biomaterials interfaced with microfabricated detection components coupled to a variety signal transduction modalities. He brings strong product development and R&D experience from the NIH/FDA, USDA, Sandia National Labs and the Intelligence Community. In addition, he has commercial senior management experience (P&L responsibility) from PSR/Veridian, CUBRC, HandyLab, and Akonni. Dr. Daitch was recruited by HandyLab Inc., a microfluidics diagnostic company, to serve on the executive management team as Vice President of R&D. Prior, Dr. Daitch launched a biodefense product development facility and business unit for PSR/Veridian Corp., a premier DOD/IC contractor, and led the growth of the operation to 24 employees and >$5M in annual revenue. As the CEO of Akonni he is responsible for 1) setting and executing strategic direction, 2) product management, 3) leading equity financing rounds (>$30M to date), managing capital, financial audits, 4) corporate governance, shareholder relations, 5) leading business development, strategic partnerships, 6) recruiting, mentoring, listening and learning from our exceptional staff, and 7) setting the company’s culture. He has 5 U.S. patents, 24 publications and served as principle investigator on over $20 million in government grants and contracts.
Follow Charles Daitch:
About Akonni Biosystems: Akonni Biosystems is a biotechnology company that develops and manufactures, genetic testing devices.
Robert C. Garrett
Founder & CEO of Hackensack Meridian Health
Robert C. Garrett is the Founder & CEO of Hackensack Meridian Health, New Jersey’s largest health network with 17 hospitals, 500 patient care locations, 34,000 team members and 6,500 physicians. Under Mr. Garrett’s visionary leadership, the network opened the Hackensack Meridian School of Medicine at Seton Hall University, formed an historic partnership with Memorial Sloan Kettering Cancer Center and secured the network’s merger with New Jersey’s largest behavioral health provider to dramatically improve access and the quality of care for addiction treatment and mental illness in New Jersey and beyond. Mr. Garrett’s leadership and strategic vision have garnered much professional praise. He was featured in The CEO Forum’s 10 CEOs Transforming Healthcare in America this year, on ROI Influencers: Power List 2019 and 2018 and was ranked #1 in the NJBIZ 2017 “Power 50 Health Care” list. He was also ranked on the 2017 “NJBIZPower 100: The most powerful people in New Jersey business” list for six consecutive years.
Follow Robert C. Garrett:
About Hackensack Meridian Health, Hackensack Meridian Health: Hackensack Meridian Health is poised to better meet the needs of their communities.
John K. Lloyd
Co CEO of Hackensack Meridian Health
Follow John K. Lloyd:
About Hackensack Meridian Health: Hackensack Meridian Health is poised to better meet the needs of their communities.
Jim Z. Lu
CEO and Medical Director of GoPath Laboratories LLC
Jim Lu, M.D., Ph.D., is the founder, CEO, and Medical Director for GoPath Laboratories. His focus is primarily on business development while he remains active with GI/Liver pathology cases and molecular test development. He received his medical degree from Wannan Medical College in Anhui, China. Afterward, he attended Johns Hopkins School of Medicine where he earned his Ph.D. in Molecular Medicine. He also successfully completed his residency and fellowship training in GI/Liver and transplant pathology at the University of Pittsburgh Medical Center. Dr. Lu has been practicing in this area of expertise for more than 15 years.
Follow Jim Z. Lu:
About GoPath Laboratories LLC: GoPath is a fully equipped, CAP Accredited and CLIA Certified Anatomic Pathology, Clinical Pathology and Molecular Diagnostic laboratory
President and Chief Executive Officer of Orchard Therapeutics
Mark brings 28 years of experience in the bio-pharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs. Prior to Orchard Therapeutics, Mark served as Chief Commercial Officer of PTC Therapeutics (“PTC”) where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. This he achieved by building a global commercialisation capability and successfully launching two rare disease therapies. Prior to joining PTC, Mark served as Global President of Aegerion Pharmaceuticals Inc. and Head EMEA region at Shire Human Genetics. Mark received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.
Follow Mark Rothera:
About Orchard Therapeutics, Silence Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Co-founder & CEO of Guardant Health
Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
Follow Helmy Eltoukhy:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Founder, Chief Executive Officer & President of PetDx
Dr. Daniel Grosu is the Founder and Managing Partner of GenoPraxis, LLC – a San Diego based specialty consultancy dedicated to enabling the practical implementation of genomic testing technologies. He is also an active angel investor, and sits on the Life Science committee of Tech Coast Angels (San Diego). Dr. Grosu previously served as Sequenom’s last Chief Medical Officer (until the company’s acquisition by LabCorp) and as Illumina’s first Chief Medical Officer. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE Marking of the MiSeqDx platform and associated cystic fibrosis assay – the world’s first NGS-based in-vitro diagnostic (IVD) product. Earlier in his career, Dr. Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.
Follow Daniel Grosu:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
CEO of IncellDx
Bruce Patterson is the CEO at IncellDx, Inc.
Follow Bruce Patterson:
About IncellDx, Stanford University School of Medicine: IncellDx is a molecular diagnostics company focused on the detection and monitoring of life threatening viral diseases.
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Founder and CEO of Subtle Medical
Enhao Gong is a PhD in Electrical Engineering (PhD Minor in Computer Science) at Stanford and researcher at Stanford School of Medicine and Subtle Medical.His research focus is on applying machine learning, deep learning and optimization for medical imaging reconstruction and processing. Specifically, he is working on fast Magnetic Resonance Imaging (MRI) algorithms, multi-contrast neuroimaging applications (MRI, PET/MR). He is advised by Professor John Pauly in Electrical Engineering and Professor Greg Zaharchuk in Radiology at Stanford.Recently he is pioneering to bridge deep learning methods with MRI reconstruction, such as enhancing image quality with Deep Learning and multi-contrast information, solving quantitative imaging (water-fat separation, QSM, parameter mapping) using Deep Learning framework as well as using Generative Adversarial Network (GAN) for Compressed Sensing MRI. At Subtle Medical, he is pushing the performance of deep learning methods to boost the efficiency and value for medical imaging.
Follow Enhao Gong:
About Subtle Medical: Subtle Medical is a healthcare technology company that offers AI-powered medical imaging.
CEO and Co Founder of Maya Health
David Champion’s passion is to create new behaviors through design. In 2005 Champion founded an educational non-profit so kids in Kenya weren’t held back from school because they couldn’t afford books. At the same time, he studied Architecture at Cambridge. Graduating at the top of my class gave me the opportunity to work with Daniel Libeskind on the master-plan for Ground Zero, and to begin my life in New York. David Champion became fascinated with Psychology and built a company curating events to bring business leaders together with psych professors, discussing better ways to harness people’s minds in business. In founding DSChampion his knowledge of software development saw us produce unique user applications for a range of clients, including Zuse Inc, infoHubs, and Baker Technologies, of which he is also co-founder.
Follow David Champion:
About Maya Health: Maya Health is a software platform designed to track, measure, and provide illustration of the health outcomes of their clients.
Co-Founder and CEO of CranioVation
Vijay graduated from Neurosurgical Residency at Duke University Hospital in 2016. He then completed specialized complex brain tumor training with the best known neurosurgeons throughout the world. He has a keen interest in brain disease, has published extensively, and has presented his research across the country and abroad. Heavily involved with innovation from an early age while growing up in Silicon Valley, he has helped launch multiple medical device companies. Vijay has been an integral part of the success of these devices in all stages, from concept and design to testing, FDA approval, and human trials. Before Duke, Vijay helped launch a posterior dynamic stabilization device that is currently in human trials. He received his BS in Electrical and Biomedical Engineering from UCLA.
Follow Vijay Agarwal:
About Alpheus Medical, CranioVation: CranioVation is an innovative solution to treat aggressive brain tumors using light delivered via a minimally invasive device.
Co-Founder & CEO of Ancera
Arjun Ganesan is Founder & CEO at Ancera.
Follow Arjun Ganesan:
About Ancera, Creative Destruction Lab (CDL): Ancera is a biotech company focused on the business of rapid cell separation and pathogen diagnostics.
Chief Executive Officer of Radiology Partners
Richard Whitney joined NEA in January 2007 as Venture Partner focusing on healthcare investments. He is the founder and Managing Member of Whitney Capital LLC, a private equity investment firm focused primarily on healthcare services and products. Previously, Rich served as Executive Chairman of Specialty Labs where he led the turnaround and successful sale of the company. Earlier, he served as Chief Financial Officer of DaVita, Inc where he was a lead executive in the company’s financial and operating turnaround which created over $3 billion of equity value for investors. Rich earned a Master’s of Business Administration from Harvard Business School and a BS in Business Administration from Pennsylvania State University.
Follow Richard Whitney:
About Elements Behavioral Health, Radiology Partners: Radiology Partners is a healthcare service company focused on transforming how services are provided by radiologists.
Chief Executive Officer, Founder & Director of Amydis, Inc.
Dr. Sarraf founded Amydis in 2013 after seeing a clinical need for diagnostics that can enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. Previously, she spent 10 years in Venture Capital at Foresite Capital Management and Prospect Venture Partners, both growth capital healthcare funds with over $1B dollars in assets under management. Some of the successful investments and exits by Foresite with Dr. Sarraf’s involvement included Wavetec Vision (sold to Alcon in 2014), Ambit Biosciences (acquired by Daiichi Sankyo in 2014 for $410M) and Auspex Pharmaceuticals (sold to Teva for $3.5B in 2015). At Prospect, she performed scientific, regulatory and commercial diligence on more than 400 investment opportunities from companies in therapeutic and diagnostic areas including the neurological and cognitive disorder space. Earlier in her career, Dr. Sarraf worked at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist responsible for creating the chemical synthesis of a novel drug for translation from the bench to production scale.
Follow Stella Sarraf:
About Amydis, Inc., Scientific Consulting, Spinogenix, Spinogenix: A pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins.
CEO of Trak
Karen Drexler currently serves Sandstone Diagnostics as the chief executive officer and board member. She is also a member of the board of directors at ResMed and a founding member of Astia Angels. Prior to this, Karen spent over six years at Hygieia working as the chairman of the board. She is also co-founded Cellscape Corporation and was the CEO of Amira Medical for over five years. Karen received her MBA from Stanford University Graduate School of Business and her BSE in chemical engineering from Princeton University.
Follow Karen Drexler:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.